ReviewInfection & chemotherapy2022
Clinical Utility of Procalcitonin on Antibiotic Stewardship: A Narrative Review.
Review in Infection & chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- The Role and Importance of Procalcitonin (PCT) Testing in Rational Antibiotic Prescribing and Antibiotic Stewardship Programs.Immunity, inflammation and disease · 2026Review
- Procalcitonin-guided antibiotic therapy in adult sepsis: A biochemical perspective from a retrospective cohort study.Journal of medical biochemistry · 2026Article
- Intratracheal obstruction caused by Haemophilus influenzae infection in young Children: Case report and literature review.Medicine · 2026Review
- A Paediatric Perspective: Opportunities and Challenges in Emergency Department Antimicrobial Stewardship.Antibiotics (Basel, Switzerland) · 2026Review
- Antimicrobial stewardship programs in sepsis treatment: principles, impact, and future directions.The Korean journal of internal medicine · 2026Review
- Elevated Serum Presepsin Identifies Herpes Simplex Virus-1 Reactivation in COVID-19 Patients.Viruses · 2025Article
- Elevated plasma soluble lectin-like oxidised low-density lipoprotein receptor 1 as an independent prognostic biomarker in sepsis.Lipids in health and disease · 2025Article
- Are Ki-67 and Procalcitonin Expression Levels Useful in Predicting the Biological Behavior of Hepatocellular Carcinoma After Liver Transplantation?Journal of clinical medicine · 2024Article
- Acute-phase proteins as indicators of disease severity and mortality in COVID-19 patients.Scientific reports · 2024Article
- A machine learning strategy to mitigate the inappropriateness of procalcitonin request in clinical practice.Heliyon · 2024Article
- Reduced Reliability of Procalcitonin (PCT) as a Biomarker of Bacterial Superinfection: Concerns about PCT-Driven Antibiotic Stewardship in Critically Ill COVID-19 Patients-Results from a Retrospective Observational Study in Intensive Care Units.Journal of clinical medicine · 2023Article
- Misleading Procalcitonin in Patients With Staphylococcus aureus Bacteremia: A Report of Two Cases.Cureus · 2023Article
- Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19.Viruses · 2023Article
- Plasma Chemerin Is Induced in Critically Ill Patients with Gram-Positive Infections.Biomedicines · 2023Article
- Utility of Procalcitonin in Clinical Practice.Journal of Brown hospital medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Procalcitonin (PCT) was discovered as a useful marker for bacterial infection. Following its discovery, there have been a substantial number of clinical studies conducted to evaluate the presence of bacterial infections, and to guide antibiotic treatment by the stratified levels of PCT. Clinical evidence suggests that antibiotic treatment by PCT-guided antibiotic stewardship has been associated with a reduction in antibiotic usage without an increase in adverse outcomes. The use of PCT was approved by the Food and Drug Administration in the United States of America in 2017 to guide antibiotic treatment in sepsis and lower respiratory tract infections (LRTIs). In Korea, the use of PCT for sepsis and for pneumonia was approved in 2015 and 2022, respectively. This review will discuss the clinical utility of PCT on antibiotic stewardship in the management of sepsis and LRTIs including pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.